LSDI: Lucy Scientific Discovery Inc. Stock

by  •  • Comments Off on LSDI: Lucy Scientific Discovery Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.38
Enterprise Value ($M) 1.23
Book Value ($M) 0.08
Book Value / Share 0.05
Price / Book 16.96
NCAV ($M) -2.87
NCAV / Share -1.63
Price / NCAV -0.48

Profitability (mra)
Return on Invested Capital (ROIC) -74.99
Return on Assets (ROA) -1.20
Return on Equity (ROE) -1.90

Liquidity (mrq)
Quick Ratio 0.38
Current Ratio 0.38

Balance Sheet (mrq) ($M)
Current Assets 1.34
Assets 4.29
Liabilities 4.21
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPOR
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-10-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT T
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-30 14,501 84,071 17.25
2024-04-29 8,657 46,388 18.66
2024-04-26 7,220 8,492 85.02
2024-04-25 9,143 10,296 88.80

(click for more detail)

Similar Companies
LPCN – Lipocine Inc. LPTX – Leap Therapeutics, Inc.
LQDA – Liquidia Corporation LSTA – Lisata Therapeutics, Inc.
LTRN – Lantern Pharma Inc.


Financial data and stock pages provided by
Fintel.io